Search Within

Human Oncology and Pathogenesis Program

Formats
  1. Journal Article (3032)
  2. Meeting Abstract (2566)
  3. Review (138)
  4. Editorial (107)
  5. Book Section (54)
  6. Research Letter (42)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (16)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. GSK Faculty (5785)
  2. Department of Medicine (4330)
  3. Department of Pathology and Laboratory Medicine (3079)
  4. Tow Center for Developmental Oncology (TCDO) (2647)
  5. Solid Tumor Oncology Division (2641)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (2589)

More Groups

People
  1. Marc Ladanyi (1335)
  2. Ross Levine (787)
  3. David Solit (782)
  4. Michael Berger (771)
  5. Nikolaus Schultz (491)
  6. Maria Arcila (428)

More People

Years
  1. 2025 (189)
  2. 2024 (381)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (650)
  2. Blood (517)
  3. Cancer Research (413)
  4. Modern Pathology (300)
  5. Clinical Cancer Research (270)
  6. Laboratory Investigation (265)

More Publications

Publishers
  1. American Association for Cancer Research (877)
  2. Nature Publishing Group (769)
  3. American Society of Clinical Oncology (718)
  4. American Society of Hematology (564)
  5. Elsevier Inc. (409)
  6. Nature Research (314)

More Publishers

Results (6005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC)
    Meeting Abstract

    Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
    Meeting Abstract

    Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
    Meeting Abstract

    Babatunde, O.; Rosenbaum, E.; Kelly, C. M.; Desir-Camille, R.; Keohan, M. L.; Banks, L.; Avutu, V.; Chan, J.; Reed, D.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Weller, M.; Berry, D. A.; Blondin, N.; Buxton, M.; Colman, H.; de Groot, J. F.; de la Fuente, M.; Ducray, F.; Ellingson, B.; Gordon, G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
    Meeting Abstract

    Tsai, C.; An, J. A. R.; Cabel, L.; Brannon, A. R.; Moiso, E.; Gedvilaite, E.; Ahmed, M.; Loudon, L.; Weipert, C.; Chou, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Ultra-sensitive ctDNA detection and monitoring in early breast cancer using PhasED-Seq
    Meeting Abstract

    Cabel, L.; An, J. A. R.; Kurtz, D.; Ross, D.; Dikoglu, E.; Chen, Y.; Murphy, K.; Szuhany, K.; Stowell, S. L.; Maloney, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save